Study shows patients treated with Smith+Nephew’s CARTIHEAL™ AGILI-C™ Cartilage Repair Implant have an 87% lower relative risk of Total Knee Arthroplasty or Osteotomy at 4 years¹*

Core Insights - Smith+Nephew's CARTIHEAL AGILI-C Cartilage Repair Implant shows promising results in treating knee cartilage defects, outperforming the current surgical standard of care in a recent multicenter randomized controlled trial [1][3][4] Product Performance - The CARTIHEAL Implant provides superior pain relief and quality of life improvements over a 4-year period, with patients reporting significantly better outcomes [6] - The implant demonstrates superior functional gains, allowing patients to perform daily activities, sports, and recreational activities more effectively at both 2 and 4 years [6] - The technology effectively treats a diverse patient population across various age groups, lesion sizes, and osteoarthritis presence, delivering clinically meaningful results [6] Clinical Significance - The CARTIHEAL Implant has shown an 87% reduction in the risk of subsequent total knee arthroplasty (TKA) and osteotomy compared to the surgical standard of care, which is a significant consideration for patients with mild to moderate osteoarthritis [4][6] - Inclusivity in study design is emphasized, with the implant showcasing superior performance across genders and lesion locations, making it a reliable option for everyday patients [4] Industry Context - The CARTIHEAL Implant is set to be featured at the Arthroscopy Association of North America Annual Meeting (AANA 2025), highlighting its role in advancing patient outcomes through education and innovation [1][3] - Smith+Nephew operates globally, with a focus on medical technology for the repair, regeneration, and replacement of soft and hard tissue, generating annual sales of $5.8 billion in 2024 [9]